- Home
- BTMD vs CLLS Comparison
BTMD vs CLLS Comparison
Compare BTMD & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- CLLS
- Stock Information
- Founded
- BTMD 2012
- CLLS 1999
- Country
- BTMD United States
- CLLS France
- Employees
- BTMD N/A
- CLLS N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- BTMD Health Care
- CLLS Health Care
- Exchange
- BTMD Nasdaq
- CLLS Nasdaq
- Market Cap
- BTMD 136.0M
- CLLS 148.1M
- IPO Year
- BTMD N/A
- CLLS 2007
- Fundamental
- Price
- BTMD $3.39
- CLLS $1.27
- Analyst Decision
- BTMD Strong Buy
- CLLS Buy
- Analyst Count
- BTMD 1
- CLLS 3
- Target Price
- BTMD $8.00
- CLLS $7.00
- AVG Volume (30 Days)
- BTMD 304.7K
- CLLS 833.7K
- Earning Date
- BTMD 03-12-2025
- CLLS 03-13-2025
- Dividend Yield
- BTMD N/A
- CLLS N/A
- EPS Growth
- BTMD N/A
- CLLS N/A
- EPS
- BTMD 0.09
- CLLS N/A
- Revenue
- BTMD $197,191,000.00
- CLLS $49,217,000.00
- Revenue This Year
- BTMD $17.51
- CLLS $1.26
- Revenue Next Year
- BTMD $15.84
- CLLS N/A
- P/E Ratio
- BTMD $38.44
- CLLS N/A
- Revenue Growth
- BTMD 6.38
- CLLS 435.38
- 52 Week Low
- BTMD $3.04
- CLLS $1.14
- 52 Week High
- BTMD $8.44
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- BTMD 34.59
- CLLS 42.61
- Support Level
- BTMD $3.04
- CLLS $1.28
- Resistance Level
- BTMD $4.47
- CLLS $1.35
- Average True Range (ATR)
- BTMD 0.33
- CLLS 0.07
- MACD
- BTMD -0.01
- CLLS 0.01
- Stochastic Oscillator
- BTMD 24.48
- CLLS 53.85
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.